Drug trial aims to tame deadly COVID-19 inflammation in hospital

NCT ID NCT04327388

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study tested whether the drug sarilumab could help hospitalized adults with severe COVID-19. Sarilumab targets inflammation, which can cause serious lung problems. The trial compared the drug to a placebo in 420 patients to see if it improved recovery, reduced the need for breathing machines, and increased survival.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigational Site Number 0320001

Caba, 1430, Argentina
Investigational Site Number 0320003

Caba, C1180AAX, Argentina
Investigational Site Number 0320004

Caba, C1426AAM, Argentina
Investigational Site Number 0760001

São Paulo, 01327-001, Brazil
Investigational Site Number 0760002

São Paulo, 04231-030, Brazil
Investigational Site Number 0760003

Porto Alegre, 90110-270, Brazil
Investigational Site Number 0760004

São José do Rio Preto, 15090-000, Brazil
Investigational Site Number 0760005

São Paulo, 04321-120, Brazil
Investigational Site Number 1240001

Montreal, H2X3E4, Canada
Investigational Site Number 1240002

Toronto, M5G 2N2, Canada
Investigational Site Number 1240003

Vancouver, V5Z 1M9, Canada
Investigational Site Number 1240004

Toronto, M4N3M5, Canada
Investigational Site Number 1240005

Montreal, H4A 3J1, Canada
Investigational Site Number 1520001

Talca, 3460001, Chile
Investigational Site Number 1520002

Santiago, 80004005, Chile
Investigational Site Number 1520003

Santiago, 750-0691, Chile
Investigational Site Number 1520004

Santiago, Chile
Investigational Site Number 2500001

Bordeaux, 33076, France
Investigational Site Number 2500002

Nantes, 44093, France
Investigational Site Number 2500003

Strasbourg, 67098, France
Investigational Site Number 2500004

Suresnes, 92151, France
Investigational Site Number 2500005

Paris, 75877, France
Investigational Site Number 2500006

La Roche-sur-Yon, 85925, France
Investigational Site Number 2500007

Clamart, 92140, France
Investigational Site Number 2760001

Münster, 48149, Germany
Investigational Site Number 2760002

Essen, 45147, Germany
Investigational Site Number 2760004

Cologne, 50937, Germany
Investigational Site Number 3760001

Ramat Gan, 52662, Israel
Investigational Site Number 3760002

Jerusalem, 91120, Israel
Investigational Site Number 3800001

Milan, 20132, Italy
Investigational Site Number 3800002

Milan, 20157, Italy
Investigational Site Number 3800003

Modena, 41100, Italy
Investigational Site Number 3800004

Parma, 43100, Italy
Investigational Site Number 3800005

Milan, 20122, Italy
Investigational Site Number 3800006

Rozzano, 20089, Italy
Investigational Site Number 3920001

Kamakura-Shi, Japan
Investigational Site Number 3920002

Fuchu-Shi, Japan
Investigational Site Number 3920003

Iruma-Gun, Japan
Investigational Site Number 6430001

Moscow, 129301, Russia
Investigational Site Number 6430002

Moscow, 123182, Russia
Investigational Site Number 6430003

Moscow, 111539, Russia
Investigational Site Number 7240001

Madrid, 28046, Spain
Investigational Site Number 7240002

Madrid, 28007, Spain
Investigational Site Number 7240003

Barcelona, 08035, Spain
Investigational Site Number 7240004

Barcelona, 08036, Spain
Investigational Site Number 7240005

Madrid, 28034, Spain
Investigational site number 3760003

Ashdod, 7747629, Israel

Conditions

Explore the condition pages connected to this study.

CORONA VIRUS INFECTION